A CLOSER LOOK
AbbVie: An Introduction

We’re a biopharmaceutical company.

We’re guided by people, powered by passion, and in awe of the possibilities ahead of us.

We’re highly focused, research-oriented, and patient-centric.

We are AbbVie.
Mission

Our mission is to build a world-class, innovation-driven, patient-focused, specialty biopharmaceutical company.

Capable of delivering top-tier performance through outstanding execution and a consistent stream of new medicines.
History

125 YEARS of patient care

Launched as AbbVie in 2013

28,000+ dedicated employees

Millions of lives touched
Impact on Science
Investing in Science

At AbbVie, we have the commitment, expertise, and capabilities to provide life-changing products to patients who need them most.

6,670+ SCIENTISTS

1 IN 10
ABBVIE EMPLOYEES CARRY A DOCTORATE
Investing in Science

There are numerous programs in mid- and late-stage development that continue to help fill our robust pipeline year over year

50+ ACTIVE CLINICAL DEVELOPMENT PROGRAMS

122,000 PATIENTS PARTICIPATED IN CLINICAL TRIALS GLOBALLY IN 2015

33,000+ PATIENTS IN THE U.S. IN 2015
Investing in Science

~ $3.6 BILLION*
INTO RESEARCH AND DEVELOPMENT IN 2015

~ 500 ABBVIE INVENTORS
CONTRIBUTED TO 100+ PATENTS IN 2015

WE’RE DISCOVERING AND TESTING
COMPOUNDS THAT COULD POTENTIALLY TREAT
482 MILLION PATIENTS

* NON-GAAP, ADJUSTED R&D SPEND
Partnerships & Collaboration

Our broad network:

Through collaboration, we advance science and innovation, the lifeblood of our company.

Recent acquisitions include
Pharmacyclics and Stemcentrx

PARTNERS INCLUDE APPROXIMATELY
270 LEADING
BIOTECHS, UNIVERSITIES, NONPROFITS,
AND GOVERNMENT ORGANIZATIONS
Therapeutic Areas of Focus

Oncology

We currently have treatment approved in relapsed/refractory Chronic Lymphocytic Leukemia with 17p deletion, Mantle Cell Lymphoma and Waldenstrom’s Macroglobulinemia. Future areas of focus include:

• Leveraging our experience in immunology to develop next-generation immuno-oncology therapies

• Growing a strong position in hematologic malignancies

• Establishing a foundation in solid tumors
Immunology

We have been leveraging deep scientific expertise to develop next-generation biologics and small molecules in rheumatology, dermatology and gastroenterology.

- ABBVIE MEDICINE TREATS + 1 MILLION PATIENTS IN 14 INDICATIONS WORLDWIDE
- 20 NEW MOLECULES TESTING IN 14 DISEASE STATES
- 196 IMMUNOLOGY STUDIES IN MORE THAN 50 COUNTRIES
Therapeutic Areas of Focus

**Virology**

AbbVie’s Hepatitis C virus (HCV) clinical development program is intended to advance scientific knowledge and the clinical care of people with chronic HCV infection.

**Neuroscience**

We’re developing innovative therapies for neurological degenerative disorders, such as Parkinson’s disease, multiple sclerosis (MS), and Alzheimer’s disease.

*AbbVie established the Foundational Neuroscience Center in Cambridge in 2016*
Focused investments in areas that fit our core strengths include:

- Endometriosis
- Uterine fibroids
- Cystic fibrosis collaborations
- Diabetic kidney disease

At AbbVie, we’re applying our significant resources toward breakthroughs in areas that touch many, at all life stages.
Impact on **Economies**
Jobs and the Economy

Globally, AbbVie creates jobs and stimulates local economies.

28,000+
 EMPLOYEES GLOBALLY

13,000+
 EMPLOYEES IN THE U.S.
Impact Worldwide

8 State-of-the-Art Research and Development Facilities
Impact Worldwide

13 Manufacturing Centers
We create global impact, through our people by their passion, reveling in possibilities.